However, the suitability of targeting CDK4/6 to protect against chemotherapy damage in the hair follicle and prevent chemotherapy‐induced alopecia in patients (i.e. via topical administration) remains to be fully elucidated in vivo. The gene discussed is CDK4; the disease is alopecia.